Odyssey Therapeutics (NASDAQ:ODTX) Upgraded to “Strong-Buy” at HC Wainwright

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by stock analysts at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. increased their price target on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating for the company. Finally, Wedbush initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Odyssey Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.75.

Odyssey Therapeutics Stock Up 1.4%

ODTX opened at $25.98 on Thursday. The stock’s fifty day moving average price is $19.57. The company has a market cap of $1.25 billion and a P/E ratio of -3.84. Odyssey Therapeutics has a 12-month low of $15.10 and a 12-month high of $28.00.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, equities analysts forecast that Odyssey Therapeutics will post -5.97 EPS for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.